Patent US1184250A successfully refreshed from Google Patents.
US6277151B1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cartilage growth from cell seeded ceramic compositions
Assignee: LIFE SCIENCE ENTERPRISES Inc
•
Filing: 1998-02-13
•
Granted: 2001-08-21
•
Expires: 2018-02-13
Abstract
Abstract The present invention provides a synthetic, poorly-crystalline apatitic (PCA) calcium phosphate material seeded with cells. Preferably, the cells are tissue-forming or tissue-degrading cells. The compositions provided by the present invention are useful for a variety of applications, including in vivo and in vitro tissue growth (preferably bone or cartilage), osseous augmentation, and methods of diagnosing disease states by assaying tissue-forming potential of cells isolated from a host. The invention also provides in vitro cell culture systems and cell encapsulation matrices.
Inventors
- 👤 Dosuk D. Lee
- 👤 Christian Rey
- 👤 Maria Aiolova
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 21:08
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/02; A61F2/28; A61F2/30; A61F2/30756; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2009; A61L; A61L24/00; A61L24/02; A61L27/00; A61L27/02; A61L27/12; A61L27/36; A61L27/38; A61L27/3804; A61L27/3821; A61L27/3839; A61L27/3843; A61L27/3847; A61L27/3852; A61L27/40; A61L27/42; A61L27/425; A61L27/50; A61L27/54; A61L27/58; C; C01; C01B; C01B25/00; C01B25/16; C01B25/26; C01B25/32; C01B25/321; C01B25/325; C04; C04B; C04B28/00; C04B28/34; C04B28/344; A61F2002/30001; A61F2002/30003; A61F2002/3006; A61F2002/30062; A61F2002/30762; A61F2/46; A61F2/4644; A61F2002/4648; A61F2210/00; A61F2210/0004; A61F2310/00; A61F2310/00005; A61F2310/00179; A61F2310/00293; A61L2300/00; A61L2300/20; A61L2300/252; A61L2300/40; A61L2300/412; A61L2300/414; A61L2300/426; A61L2300/60; A61L2300/64; A61L2400/00; A61L2400/06; A61L2430/00; A61L2430/02; C04B2111/00; C04B2111/00474; C04B2111/00836; Y; Y10; Y10S; Y10S623/00; Y10S623/915; Y10S623/919
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
96 words
A method of growing cartilage in vivo comprising: a. providing a hydrated precursor comprising: i. at least one amorphous calcium phosphate (ACP); ii. at least one cartilage-forming cell or precursor thereof; and iii. a sufficient amount of aqueous solution so that the hydrated precursor has a consistency selected from the group consisting of a paste consistency and a putty consistency, the aqueous solution being compatible with the at least one cartilage-forming cell or precursor thereof; b. introducing the hydrated precursor into a site in vivo; and c. after step a, allowing the hydrated precursor to harden.
Claim 2
Independent Claim
96 words
A method of growing cartilage in vivo comprising: a. providing a hydrated precursor comprising: i. at least one amorphous calcium phosphate (ACP); ii. at least one cartilage-forming cell or precursor thereof; and iii. a sufficient amount of aqueous solution so that the hydrated precursor has a consistency selected from the group consisting of a paste consistency and a putty consistency, the aqueous solution being compatible with the at least one cartilage-forming cell or precursor thereof; b. introducing the hydrated precursor into a site in vivo; and c. after step a, allowing the hydrated precursor to harden.
Claim 3
Independent Claim
93 words
A method of growing cartilage in vivo comprising: a. providing a hydrated precursor comprising: i. at least one amorphous calcium phosphate (ACP); and ii. a sufficient amount of aqueous solution so that the hydrated precursor has a consistency selected from the group consisting of a paste consistency and a putty consistency; b. introducing the hydrated precursor into a site in vivo; c. promoting conversion of the ACP into a poorly crystalline apatitic (PCA) calcium phosphate after the step of introducing; and d. allowing cartilage-forming cells or precursors thereof to enter the implanted material.
Claim 4
Independent Claim
93 words
A method of growing cartilage in vivo comprising: a. providing a hydrated precursor comprising: i. at least one amorphous calcium phosphate (ACP); and ii. a sufficient amount of aqueous solution so that the hydrated precursor has a consistency selected from the group consisting of a paste consistency and a putty consistency; b. introducing the hydrated precursor into a site in vivo; c. promoting conversion of the ACP into a poorly crystalline apatitic (PCA) calcium phosphate after the step of introducing; and d. allowing cartilage-forming cells or precursors thereof to enter the implanted material.
Claim 5
Dependent Claim
37 words
The method of claim 1 , wherein the hydrated precursor further comprises a biologically active agent that attracts cartilage-forming cells or precursors thereof so that, after implantation, cartilage-forming cells or precursors thereof migrate into the implanted material.
Claim 6
Dependent Claim
27 words
The method of claim 1 , wherein the hydrated precursor is characterized by a tendency to harden at 22° C. after a time longer than one hour.
Claim 7
Dependent Claim
27 words
The method of claim 1 , wherein the hydrated precursor is characterized by a tendency to harden at 37° C. after a time shorter than one hour.
Claim 8
Dependent Claim
26 words
The method of claim 1 , further comprising the step of promoting the conversion of the hydrated precursor into a hardened poorly crystalline apatitic calcium phosphate.
Claim 9
Dependent Claim
15 words
The method of claim 1 , wherein the hydrated precursor further comprises a therapeutic agent.
Claim 10
Dependent Claim
16 words
The method of claim 1 , wherein the hydrated precursor further comprises a second calcium phosphate.
Claim 11
Dependent Claim
17 words
The method of claim 1 , wherein the amorphous calcium phosphate has a Ca/P ratio between 1.1-1.9.
Claim 12
Dependent Claim
45 words
The method of claim 8 , wherein the second calcium phosphate is selected from the group consisting of calcium metaphosphate, dicalcium phosphate dihydrate, heptacalcium decaphosphate, tricalcium phosphates, calcium pyrophosphate dihydrate, poorly crystalline apatitic calcium phosphate, calcium pyrophosphate, octacalcium phosphate, tetracalcium phosphate, and amorphous calcium phosphate.
Claim 13
Dependent Claim
15 words
The method of claim 8 , wherein the second calcium phosphate is dicalcium phosphate dihydrate.
Claim 14
Dependent Claim
15 words
The method of claim 8 , wherein the second calcium phosphate is calcium deficient hydroxyapatite.
Claim 15
Dependent Claim
45 words
The method of claim 6 , wherein the step of promoting conversion involves exposing the hydrated precursor to appropriate conditions for a time sufficient that a poorly crystalline apatitic calcium phosphate characterized by a calcium to phosphate ratio of less than about 1.5 is produced.
Claim 16
Dependent Claim
22 words
The method of claim 1 , further comprising the step of shaping the hydrated precursor into a predetermined form prior to hardening.
Claim 17
Dependent Claim
58 words
The method of claim 8 , wherein the hydrated precursor further comprises a supplementary material selected to change a physical parameter of the paste or the hardened product, said parameter selected from the group consisting of strength, resorption time, adherence, injectability, frictional characteristics, release kinetics, tensile strength, hardness, fracture toughness, elasticity, imaging capability, flow properties and setting times.
Claim 18
Dependent Claim
25 words
The method of claim 1 , wherein said cartilage-forming cell is introduced into said hydrated precursor by allowing said cell to enter the hydrated precursor.
Claim 19
Dependent Claim
37 words
The method of claim 2 , wherein the hydrated precursor further comprises a biologically active agent that attracts cartilage-forming cells or precursors thereof so that, after implantation, cartilage-forming cells or precursors thereof migrate into the implanted material.
Claim 20
Dependent Claim
27 words
The method of claim 2 , wherein the hydrated precursor is characterized by a tendency to harden at 22° C. after a time longer than one hour.
Claim 21
Dependent Claim
27 words
The method of claim 2 , wherein the hydrated precursor is characterized by a tendency to harden at 37° C. after a time shorter than one hour.
Claim 22
Dependent Claim
15 words
The method of claim 2 , wherein the hydrated precursor further comprises a therapeutic agent.
Claim 23
Dependent Claim
16 words
The method of claim 2 , wherein the hydrated precursor further comprises a second calcium phosphate.
Claim 24
Dependent Claim
17 words
The method of claim 2 , wherein the amorphous calcium phosphate has a Ca/P ratio between 1.1-1.9.
Claim 25
Dependent Claim
37 words
The method of claim 21 , wherein the second calcium phosphate is selected from the group consisting of calcium metaphosphate, dicalcium phosphate, dihydrate, heptacalcium decaphosphate, tricalcium phosphates, calcium pyrophosphate, octacalcium phosphate, tetracalcium phosphate, and amorphous calcium phosphate.
Claim 26
Dependent Claim
15 words
The method of claim 21 , wherein the second calcium phosphate is dicalcium phosphate dihydrate.
Claim 27
Dependent Claim
15 words
The method of claim 21 , wherein the second calcium phosphate is calcium deficient hydroxyapatite.
Claim 28
Dependent Claim
22 words
The method of claim 2 , further comprising the step of shaping the hydrated precursor into a predetermined form prior to hardening.
Claim 29
Dependent Claim
58 words
The method of claim 21 , wherein the hydrated precursor further comprises a supplementary material selected to change a physical parameter of the paste or the hardened product, said parameter selected from the group consisting of strength, resorption time, adherence, injectability, frictional characteristics, release kinetics, tensile strength, hardness, fracture toughness, elasticity, imaging capability, flow properties and setting times.
References Cited (Backward Citations)
US4157378A
Cited
US4347234A
Cited
US4429691A
Cited
US4346709A
Cited
US4353888A
Cited
USRE33161E
Cited
USRE33221E
Cited
US5286763A
Cited
US4842603A
Cited
US4612053A
Cited
US4609551A
Cited
US4684673A
Cited
US4620327A
Cited
US4917702A
Cited
US5007930A
Cited
US4959104A
Cited
JPS63111875A
Cited
EP0268463A2
Cited
US5041138A
Cited
US4737411A
Cited
JPS63170205A
Cited
US5085861A
Cited
US4938938A
Cited
US4892538A
Cited
US5336264A
Cited
US5047031A
Cited
US5053212A
Cited
US4880610A
Cited
EP0347028A2
Cited
US5129905A
Cited
US5178845A
Cited
US4849193A
Cited
JPH02182261A
Cited
US5034059A
Cited
US5037639A
Cited
US5164187A
Cited
US5279831A
Cited
WO1992000109A1
Cited
WO1992002453A1
Cited
US5152836A
Cited
US5197985A
Cited
US5226914A
Cited
US5486359A
Cited
US5149368A
Cited
US5262166A
Cited
US5342441A
Cited
US5281265A
Cited
US5352715A
Cited
WO1994002412A1
Cited
WO1994004657A1
Cited
JPH06228011A
Cited
US5399665A
Cited
JPH07277712A
Cited
US5514378A
Cited
WO1994020064A1
Cited
US5522893A
Cited
US5545254A
Cited
US5542973A
Cited
US5691397A
Cited
US5565502A
Cited
WO1994025080A1
Cited
US5470803A
Cited
EP0664133A1
Cited
US5525148A
Cited
WO1995008319A1
Cited
WO1996003160A1
Cited
US5516532A
Cited
US5496399A
Cited
US5904716A
Cited
WO1996036562A1
Cited
US5605712A
Cited
US5700289A
Cited
WO1997017285A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2004-08-20 | 2005-02-19 | 2005-08-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2008-08-20 | 2009-02-19 | 2009-08-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2012-08-20 | 2013-02-19 | 2013-08-21 | $7700.00 | Window Closed / Lapsed |